drug
remdesivir
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for viral disease and covid-19 and 3 investigational indications.
all catalysts(23)
approval · 23
Oct 22, 2020
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Feb 22, 2021
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jan 19, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jan 21, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Mar 24, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Apr 25, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jun 24, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Sep 29, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Oct 24, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Dec 15, 2022
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Mar 29, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Apr 28, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jun 7, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jun 12, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jul 13, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Aug 17, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Aug 23, 2023
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Feb 28, 2024
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jun 27, 2024
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Dec 19, 2024
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Jan 10, 2025
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Aug 22, 2025
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Oct 7, 2025
approval
$GILD138.36+0.16%
VEKLURY (REMDESIVIR) — FDA approval
remdesivir
→
Trials studying remdesivir
- phase3A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- phase2Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase3ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
- phase3Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
- phase2Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
- N/ASARS-CoV-2 Human Challenge Characterisation Study
- phase1A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 13, 2027
151 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (58)
- Nov 28, 2041patentUS 11491169*PED
- Nov 28, 2041patentUS 11491169*PED
- Nov 28, 2041patentUS 11903953*PED
- Nov 28, 2041patentUS 11903953*PED
- Nov 28, 2041patentUS 11975012*PED
- Nov 28, 2041patentUS 11975012*PED
- May 28, 2041method-of-use (U-3835)US 11491169
- May 28, 2041method-of-use (U-3833)US 11491169
- May 28, 2041method-of-use (U-3834)US 11903953
- May 28, 2041method-of-use (U-3836)US 11903953
- May 28, 2041method-of-use (U-3836)US 11975012
- May 28, 2041method-of-use (U-3834)US 11975012
- Jan 10, 2039patentUS 10675296*PED
- Jan 10, 2039patentUS 11266681*PED
- Jan 10, 2039patentUS 11975017*PED
- Jul 10, 2038formulationUS 10675296
- Jul 10, 2038method-of-use (U-3831)US 11266681
- Jul 10, 2038formulationUS 11975017
- Mar 16, 2037patentUS 10695361*PED
- Mar 16, 2037patentUS 10695361*PED
- Mar 16, 2037patentUS 11007208*PED
- Mar 16, 2037patentUS 11007208*PED
- Mar 16, 2037patentUS 11382926*PED
- Mar 16, 2037patentUS 11382926*PED
- Sep 16, 2036method-of-use (U-3832)US 10695361
- Sep 16, 2036method-of-use (U-3830)US 10695361
- Sep 16, 2036method-of-use (U-3830)US 11007208
- Sep 16, 2036method-of-use (U-3832)US 11007208
- Sep 16, 2036method-of-use (U-3832)US 11382926
- Sep 16, 2036method-of-use (U-3829)US 11382926
- Apr 29, 2036patentUS 9724360*PED
- Apr 29, 2036patentUS 9724360*PED
- Apr 29, 2036patentUS 9949994*PED
- Apr 29, 2036patentUS 9949994*PED
- Oct 29, 2035compositionUS 9724360
- Oct 29, 2035compositionUS 9724360
- Oct 29, 2035compositionUS 9949994
- Oct 29, 2035compositionUS 9949994
- Jun 8, 2032patentUS 11492353*PED
- Jun 8, 2032patentUS 11492353*PED
- Mar 16, 2032patentUS 10065958*PED
- Mar 16, 2032patentUS 10065958*PED
- Dec 8, 2031compositionUS 11492353
- Dec 8, 2031compositionUS 11492353
- Sep 16, 2031compositionUS 10065958
- Sep 16, 2031compositionUS 10065958
- Mar 6, 2030patentUS 8008264*PED3.6y
- Mar 6, 2030patentUS 8008264*PED3.6y
- Oct 22, 2029patentUS 8318682*PED3.2y
- Oct 22, 2029patentUS 8318682*PED3.2y
- Oct 22, 2029patentUS RE46762*PED3.2y
- Oct 22, 2029patentUS RE46762*PED3.2y
- Sep 6, 2029compositionUS 80082643.1y
- Sep 6, 2029compositionUS 80082643.1y
- Apr 22, 2029compositionUS 83186822.7y
- Apr 22, 2029compositionUS 83186822.7y
- Apr 22, 2029compositionUS RE467622.7y
- Apr 22, 2029compositionUS RE467622.7y
FDA exclusivities (8)
- Jan 13, 2027PEDPediatric (6mo bonus)151d
- Jan 13, 2027PEDPediatric (6mo bonus)151d
- Jul 13, 2026M-301Method (3y)
- Jul 13, 2026M-301Method (3y)
- Apr 22, 2026PEDPediatric (6mo bonus)
- Apr 22, 2026PEDPediatric (6mo bonus)
- Oct 22, 2025NCENew Chemical Entity (5y)
- Oct 22, 2025NCENew Chemical Entity (5y)
News(5)
- Opinion: We prepared for Ebola — but not this Ebola“Preparedness cannot mean optimizing every investment for yesterday's epidemic,” write Krutika Kuppalli and Placide Mbala.stat · 4d ago
- Opinion: We prepared for Ebola — but not this Ebola“Preparedness cannot mean optimizing every investment for yesterday's epidemic,” write Krutika Kuppalli and Placide Mbala.stat · 4d ago
- The race for an Ebola therapy beginsMale marathoners "hit the wall," mental health in 2026, and more Morning Rounds newsstat · 1mo ago
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and morePharma updates from the Pharmalot campus via the Pharmalittle newsletterstat · 2mo ago
- Which vaccines will curb the Ebola outbreak? WHO debatesThe growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Roundsstat · 2mo ago
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that